Cases & Deals

Atlas Venture invests in Novexel

Clients Atlas Venture

Jones Day advised Atlas Venture in connection with its purchase of €50 million ($64.6 million) of Series B Convertible Preferred Stock in a private placement by Novexel SA, a pharmaceutical company focused on the discovery and development of novel antibiotics and anti-fungals.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.